adenine has been researched along with Lymphoma in 54 studies
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "2-Amino-N6-hydroxyadenine (AHA) was tested in the mouse lymphoma L5178Y tk +/- assay using the microtitre cloning technique over concentrations from 0." | 7.68 | The mutagenicity of 2-amino-N6-hydroxyadenine to L5178Y tk +/- 3.7.2C mouse lymphoma cells: measurement of mutations to ouabain, 6-thioguanine and trifluorothymidine resistance, and the induction of micronuclei. ( Bridges, BA; Cole, J; Richmond, FN, 1991) |
| "2-Amino-N6-hydroxyadenine (AHA) was tested in the mouse lymphoma L5178Y tk +/- assay using the microtitre cloning technique over concentrations from 0." | 3.68 | The mutagenicity of 2-amino-N6-hydroxyadenine to L5178Y tk +/- 3.7.2C mouse lymphoma cells: measurement of mutations to ouabain, 6-thioguanine and trifluorothymidine resistance, and the induction of micronuclei. ( Bridges, BA; Cole, J; Richmond, FN, 1991) |
| "Twenty-six patients with advanced cancer underwent acetylator phenotyping with caffeine and were assigned to a dose level." | 2.67 | Phase I study of amonafide dosing based on acetylator phenotype. ( Berezin, F; Janisch, L; Lane, LB; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 1993) |
| " Here side effects of ibrutinib have been summarized and important considerations in the management of these adverse events have been reviewed." | 2.61 | Management of adverse effects/toxicity of ibrutinib. ( Paydas, S, 2019) |
| " KIN-8194 demonstrated excellent bioavailability and pharmacokinetic parameters, with good tolerance in rodent models at pharmacologically achievable and active doses." | 1.62 | The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. ( Anderson, KC; Buhrlage, SJ; Cameron, M; Castillo, JJ; Che, J; Chen, JG; Demos, MG; Gray, NS; Guerrera, ML; Hunter, ZR; Kofides, A; Liu, X; Meid, K; Munshi, M; Munshi, NC; Patterson, CJ; Tan, L; Treon, SP; Tsakmaklis, N; Wang, J; Xu, L; Yang, G, 2021) |
| "Increased aspergillosis was observed with ibrutinib monotherapy and DA-TEDDi-R." | 1.46 | Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. ( Bhaumik, S; Butman, JA; Ceribelli, M; Chen, L; Cole, DE; Desai, JV; Dunleavy, K; Gea-Banacloche, J; Heiss, J; Higham, CS; Jaffe, ES; Lionakis, MS; Little, RF; Lucas, N; Melani, C; Pittaluga, S; Roschewski, M; Schmitz, R; Staudt, LM; Steinberg, SM; Stetler-Stevenson, M; Thomas, CJ; Widemann, BC; Wilson, WH; Yang, Y, 2017) |
| "We report a case of autoimmune thrombocytopenia associated with acute reverse seroconversion of hepatitis B in a patient who was initially hepatitis B virus surface antigen negative and hepatitis B virus surface antibody positive." | 1.34 | [Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation]. ( Aubourg, A; Bacq, Y; d'Alteroche, L; Gaudy, C; Senecal, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (31.48) | 18.7374 |
| 1990's | 6 (11.11) | 18.2507 |
| 2000's | 4 (7.41) | 29.6817 |
| 2010's | 16 (29.63) | 24.3611 |
| 2020's | 11 (20.37) | 2.80 |
| Authors | Studies |
|---|---|
| Malfona, F | 1 |
| Testi, AM | 1 |
| Moleti, ML | 1 |
| Petrucci, L | 1 |
| Leccisotti, L | 1 |
| Martelli, M | 1 |
| Di Rocco, A | 1 |
| Jimenez, JE | 1 |
| Dai, D | 1 |
| Xu, G | 1 |
| Zhao, R | 1 |
| Li, T | 1 |
| Pan, T | 1 |
| Wang, L | 1 |
| Lin, Y | 1 |
| Wang, Z | 1 |
| Jaffray, D | 1 |
| Hazle, JD | 1 |
| Macapinlac, HA | 1 |
| Wu, J | 1 |
| Lu, Y | 1 |
| Grainger, BT | 1 |
| Issa, S | 2 |
| Lauer, EM | 1 |
| Waterhouse, M | 1 |
| Braig, M | 1 |
| Mutter, J | 1 |
| Bleul, S | 1 |
| Duque-Afonso, J | 1 |
| Duyster, J | 1 |
| Marks, R | 1 |
| Reinacher, PC | 1 |
| Prinz, M | 1 |
| Illerhaus, G | 1 |
| Finke, J | 1 |
| Schorb, E | 1 |
| Scherer, F | 1 |
| Lewis, KL | 1 |
| Chin, CK | 1 |
| Manos, K | 1 |
| Casey, J | 1 |
| Hamad, N | 1 |
| Crawford, J | 1 |
| Ho, SJ | 1 |
| Grigg, A | 1 |
| Wood, P | 1 |
| Gandhi, MK | 1 |
| Do, B | 1 |
| Nastoupil, L | 1 |
| Hawkes, EA | 1 |
| Cheah, CY | 1 |
| Chen, F | 1 |
| Pang, D | 1 |
| Guo, H | 1 |
| Ou, Q | 1 |
| Wu, X | 1 |
| Jiang, X | 1 |
| Wei, X | 1 |
| Liu, S | 1 |
| Huang, L | 1 |
| Liang, Z | 1 |
| Zhou, D | 1 |
| Li, W | 1 |
| Meitlis, I | 1 |
| Allenspach, EJ | 1 |
| Bauman, BM | 1 |
| Phan, IQ | 1 |
| Dabbah, G | 1 |
| Schmitt, EG | 1 |
| Camp, ND | 1 |
| Torgerson, TR | 1 |
| Nickerson, DA | 1 |
| Bamshad, MJ | 1 |
| Hagin, D | 1 |
| Luthers, CR | 1 |
| Stinson, JR | 1 |
| Gray, J | 1 |
| Lundgren, I | 1 |
| Church, JA | 1 |
| Butte, MJ | 1 |
| Jordan, MB | 1 |
| Aceves, SS | 1 |
| Schwartz, DM | 1 |
| Milner, JD | 1 |
| Schuval, S | 1 |
| Skoda-Smith, S | 1 |
| Cooper, MA | 1 |
| Starita, LM | 1 |
| Rawlings, DJ | 1 |
| Snow, AL | 1 |
| James, RG | 1 |
| Claves, F | 1 |
| Siest, R | 1 |
| Lefebvre, C | 1 |
| Valmary-Degano, S | 1 |
| Carras, S | 1 |
| Yang, G | 1 |
| Wang, J | 1 |
| Tan, L | 1 |
| Munshi, M | 1 |
| Liu, X | 1 |
| Kofides, A | 1 |
| Chen, JG | 1 |
| Tsakmaklis, N | 1 |
| Demos, MG | 1 |
| Guerrera, ML | 1 |
| Xu, L | 1 |
| Hunter, ZR | 1 |
| Che, J | 1 |
| Patterson, CJ | 1 |
| Meid, K | 1 |
| Castillo, JJ | 1 |
| Munshi, NC | 1 |
| Anderson, KC | 1 |
| Cameron, M | 1 |
| Buhrlage, SJ | 1 |
| Gray, NS | 1 |
| Treon, SP | 1 |
| Gángó, A | 1 |
| Kiss, R | 1 |
| Farkas, P | 1 |
| Hanna, E | 1 |
| Demeter, J | 1 |
| Deák, B | 1 |
| Lévai, D | 1 |
| Kotmayer, L | 1 |
| Alpár, D | 1 |
| Matolcsy, A | 1 |
| Bödör, C | 1 |
| Mátrai, Z | 1 |
| Timár, B | 1 |
| Feldman, RC | 1 |
| Hyman, DA | 1 |
| Price, WN | 1 |
| Ratain, MJ | 2 |
| Lionakis, MS | 1 |
| Dunleavy, K | 1 |
| Roschewski, M | 1 |
| Widemann, BC | 1 |
| Butman, JA | 1 |
| Schmitz, R | 1 |
| Yang, Y | 1 |
| Cole, DE | 1 |
| Melani, C | 1 |
| Higham, CS | 1 |
| Desai, JV | 1 |
| Ceribelli, M | 1 |
| Chen, L | 1 |
| Thomas, CJ | 1 |
| Little, RF | 1 |
| Gea-Banacloche, J | 1 |
| Bhaumik, S | 1 |
| Stetler-Stevenson, M | 1 |
| Pittaluga, S | 1 |
| Jaffe, ES | 1 |
| Heiss, J | 1 |
| Lucas, N | 1 |
| Steinberg, SM | 1 |
| Staudt, LM | 1 |
| Wilson, WH | 1 |
| Guha, A | 1 |
| Derbala, MH | 1 |
| Zhao, Q | 1 |
| Wiczer, TE | 1 |
| Woyach, JA | 1 |
| Byrd, JC | 1 |
| Awan, FT | 1 |
| Addison, D | 1 |
| Grommes, C | 1 |
| Tang, SS | 1 |
| Wolfe, J | 1 |
| Kaley, TJ | 1 |
| Daras, M | 1 |
| Pentsova, EI | 1 |
| Piotrowski, AF | 1 |
| Stone, J | 1 |
| Lin, A | 1 |
| Nolan, CP | 1 |
| Manne, M | 1 |
| Codega, P | 1 |
| Campos, C | 1 |
| Viale, A | 1 |
| Thomas, AA | 1 |
| Berger, MF | 1 |
| Hatzoglou, V | 1 |
| Reiner, AS | 1 |
| Panageas, KS | 1 |
| DeAngelis, LM | 1 |
| Mellinghoff, IK | 1 |
| Tarantelli, C | 1 |
| Gaudio, E | 1 |
| Cascione, L | 1 |
| Stathis, A | 1 |
| Zucca, E | 1 |
| Bertoni, F | 1 |
| Paydas, S | 1 |
| Soussain, C | 2 |
| Choquet, S | 2 |
| Blonski, M | 1 |
| Leclercq, D | 1 |
| Houillier, C | 2 |
| Rezai, K | 1 |
| Bijou, F | 1 |
| Houot, R | 1 |
| Boyle, E | 2 |
| Gressin, R | 1 |
| Nicolas-Virelizier, E | 1 |
| Barrie, M | 1 |
| Moluçon-Chabrot, C | 1 |
| Lelez, ML | 1 |
| Clavert, A | 1 |
| Coisy, S | 1 |
| Leruez, S | 1 |
| Touitou, V | 1 |
| Cassoux, N | 1 |
| Daniau, M | 1 |
| Ertault de la Bretonnière, M | 1 |
| El Yamani, A | 1 |
| Ghesquières, H | 1 |
| Hoang-Xuan, K | 2 |
| Vargas, L | 1 |
| Hamasy, A | 1 |
| Nore, BF | 1 |
| Smith, CI | 1 |
| Turetsky, A | 1 |
| Kim, E | 1 |
| Kohler, RH | 1 |
| Miller, MA | 1 |
| Weissleder, R | 1 |
| Sagiv-Barfi, I | 1 |
| Kohrt, HE | 1 |
| Burckhardt, L | 1 |
| Czerwinski, DK | 1 |
| Levy, R | 1 |
| Grisafi, D | 1 |
| Maestro, A | 1 |
| Grumi, C | 1 |
| Piazzoni, L | 1 |
| Tirone, G | 1 |
| Fiore, W | 1 |
| Tessari, R | 1 |
| Gianardi, V | 1 |
| Gatti, M | 1 |
| Tasca, F | 1 |
| Generali, D | 1 |
| Ravelli, A | 1 |
| Lanza, F | 1 |
| Scaglione, F | 1 |
| Iida, S | 1 |
| Cheson, BD | 1 |
| Leong, DP | 1 |
| Caron, F | 1 |
| Hillis, C | 1 |
| Duan, A | 1 |
| Healey, JS | 1 |
| Fraser, G | 1 |
| Siegal, D | 1 |
| Cai, Q | 1 |
| Chen, K | 1 |
| Chen, J | 1 |
| Wu, S | 1 |
| Geng, Q | 1 |
| Huang, H | 1 |
| Lin, T | 1 |
| Jiang, W | 1 |
| Xia, Z | 1 |
| Duan, H | 1 |
| Rao, H | 1 |
| Yao, M | 1 |
| Hu, L | 1 |
| Chamoun, K | 1 |
| Larrieu-Ciron, D | 1 |
| Al Jijakli, A | 1 |
| Delrieu, V | 1 |
| Delwail, V | 1 |
| Morschhauser, F | 1 |
| Feeney, SA | 1 |
| McCaughey, C | 1 |
| Watt, AP | 1 |
| Agnaf, MR | 1 |
| McDougall, N | 1 |
| Wend, UC | 1 |
| Gerlich, WH | 1 |
| Coyle, PV | 1 |
| SARTORELLI, AC | 4 |
| UPCHURCH, HF | 1 |
| BIEBER, AL | 1 |
| CHANG, PK | 1 |
| FISCHER, GA | 1 |
| Goursaud, S | 1 |
| Pineau, N | 1 |
| Becq-Giraudon, L | 1 |
| Gressens, P | 1 |
| Muller, JM | 1 |
| Janet, T | 1 |
| Sharif, FA | 1 |
| Yilmaz, Y | 1 |
| Zieske, A | 1 |
| Qumsiyeh, MB | 1 |
| Aubourg, A | 1 |
| d'Alteroche, L | 1 |
| Senecal, D | 1 |
| Gaudy, C | 1 |
| Bacq, Y | 1 |
| Zápotocký, M | 1 |
| Hanzalová, J | 1 |
| Starková, J | 1 |
| Votruba, I | 1 |
| Holý, A | 1 |
| Otová, B | 1 |
| Nguyen, BT | 1 |
| El Sayed, YM | 1 |
| Sadée, W | 2 |
| Buchwald, M | 1 |
| Ullman, B | 4 |
| Martin, DW | 1 |
| Makukho, LV | 1 |
| Volkolupova, OP | 1 |
| Mick, R | 1 |
| Berezin, F | 1 |
| Janisch, L | 1 |
| Schilsky, RL | 1 |
| Vogelzang, NJ | 1 |
| Lane, LB | 1 |
| Morgan, AJ | 1 |
| Murray, KJ | 1 |
| Challiss, RA | 1 |
| Clive, D | 1 |
| Glover, P | 1 |
| Krehl, R | 1 |
| Poorman-Allen, P | 1 |
| Evans, HH | 1 |
| Mencl, J | 1 |
| Ricanati, M | 1 |
| DiSalvo, C | 1 |
| Varnes, ME | 1 |
| Cole, J | 1 |
| Richmond, FN | 1 |
| Bridges, BA | 1 |
| Hanson, S | 2 |
| McCartan, K | 1 |
| Sabina, RL | 1 |
| Holmes, EW | 1 |
| Beck, J | 1 |
| Duan, DS | 1 |
| Plagemann, PG | 1 |
| Wohlhueter, RM | 1 |
| Adamson, RH | 1 |
| Ablashi, DV | 1 |
| Cicmanec, JL | 1 |
| Dalgard, DW | 1 |
| Tyrsted, G | 1 |
| Warnick, CT | 1 |
| Kim, SC | 1 |
| Paterson, AR | 1 |
| Fuska, J | 1 |
| Ivanitskaya, L | 1 |
| Horáková, K | 1 |
| Kuhr, I | 1 |
| Frei, JV | 1 |
| Robins, AB | 1 |
| Taylor, DM | 1 |
| Mandel, LR | 1 |
| Srinivasan, PR | 1 |
| Borek, E | 1 |
| Tsunamura, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors[NCT05643235] | 50 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCN[NCT02315326] | Phase 1/Phase 2 | 109 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma[NCT02542514] | Phase 2 | 52 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for adenine and Lymphoma
| Article | Year |
|---|---|
Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature.
Topics: Adenine; Female; Humans; Lymphoma; Meningeal Carcinomatosis; Middle Aged; Piperidines; Pyrazoles; Py | 2020 |
Management of adverse effects/toxicity of ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug-Related Side Effects and Adv | 2019 |
Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Antineoplastic Agents; Autoimmunit | 2013 |
Ibrutinib: from bench side to clinical implications.
Topics: Adenine; Antineoplastic Agents; Biomedical Research; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; | 2015 |
Overview: A New Era of Cancer Genomics in Lymphoid Malignancies.
Topics: Adenine; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Genome, Human; Genomics | 2015 |
Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
Topics: Adenine; Clinical Trials as Topic; Drug Design; Humans; Lymphoma; Piperidines; Purines; Pyrazoles; P | 2016 |
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Incidence; Leuke | 2016 |
4 trials available for adenine and Lymphoma
| Article | Year |
|---|---|
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Disease-Free Survival; Fe | 2021 |
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Com | 2019 |
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) net
Topics: Adenine; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Femal | 2019 |
Phase I study of amonafide dosing based on acetylator phenotype.
Topics: Acetylation; Adenine; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; | 1993 |
43 other studies available for adenine and Lymphoma
| Article | Year |
|---|---|
Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Topics: Adenine; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma; Lymphoma, B-Cel | 2022 |
Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma.
Topics: Adenine; Fluorodeoxyglucose F18; Humans; Lymphoma; Piperidines; Positron Emission Tomography Compute | 2022 |
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Topics: Adenine; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; | 2020 |
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Prot | 2020 |
Multiplexed Functional Assessment of Genetic Variants in CARD11.
Topics: Adenine; B-Cell CLL-Lymphoma 10 Protein; B-Lymphocytes; CARD Signaling Adaptor Proteins; Cell Line; | 2020 |
Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma.
Topics: Adenine; Female; Humans; Interleukin-1; Lymphoma; Middle Aged; Piperidines; Schnitzler Syndrome | 2021 |
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug | 2021 |
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Genes, | 2022 |
Negative innovation: when patents are bad for patients.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia; Lymphoma; Patents as Topic; Patient Harm; Piperidi | 2021 |
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Animals; Aspergillosis; Brain | 2017 |
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cohort Studies; Female; Follow-Up Studies; Human | 2018 |
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Huma | 2019 |
Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Binding Sites; Cell Line, Tumor; Gene Express | 2014 |
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.
Topics: Adenine; Adjuvants, Immunologic; Animals; Cell Line; Drug Synergism; Female; Injections, Intralesion | 2015 |
The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; DNA, Viral; Drug Inter | 2016 |
Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
Topics: Adenine; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Follow-Up Studies; H | 2017 |
Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; DNA, | 2013 |
PHYSIOLOGICAL DISPOSITION AND THERAPEUTIC CONSEQUENCES OF ADENINE ADMINISTERED VIA THE GASTROINTESTINAL TRACT IN NORMAL AND TUMOR-BEARING MICE.
Topics: Adenine; Adenine Nucleotides; Animals; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatoc | 1963 |
SOME INHIBITORY PROPERTIES OF 6-N-HYDROXYLAMINOPURINE: AN ANALOG OF ADENINE AND HYPOXANTHINE.
Topics: Adenine; Adenine Nucleotides; Animals; Antimetabolites; Carbon Isotopes; Glycine; Guanine Nucleotide | 1964 |
Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Topics: Adenine; Adenylyl Cyclase Inhibitors; Analysis of Variance; Blotting, Southern; Bromodeoxyuridine; C | 2005 |
Natural killer cell lymphoma/leukemia with homozygous loss of p27/kip1.
Topics: Adenine; Aged; Amino Acid Sequence; Base Sequence; Cyclin-Dependent Kinase Inhibitor p27; Cytogeneti | 2005 |
[Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation].
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Hematopoietic Stem Cell T | 2007 |
Experimental therapy with 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP): origin of resistance.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expressio | 2007 |
Interaction among the distinct effects of adenine and guanine depletion in mouse lymphoma cells.
Topics: Adenine; Adenosine; Alanine; Animals; Antimetabolites, Antineoplastic; Cell Division; DNA Replicatio | 1984 |
Biochemical and genetic analysis of AMP deaminase deficiency in cultured mammalian cells.
Topics: Adenine; AMP Deaminase; Animals; Cell Division; Cell Line; Guanosine Triphosphate; Kinetics; Lymphom | 1981 |
[Use of an express method in studying the cytotoxic action of antitumor antibiotics].
Topics: Adenine; Animals; Antibiotics, Antineoplastic; Carbon Radioisotopes; Cells, Cultured; Drug Evaluatio | 1981 |
Comparison of methods to assess cyclic AMP turnover under conditions of agonist stimulation in 1321N1 astrocytoma cells.
Topics: Adenine; Adenosine Triphosphate; Animals; Astrocytoma; Carbon Radioisotopes; Cell Line; Cyclic AMP; | 1992 |
Mutagenicity of 2-amino-N6-hydroxyadenine (AHA) at three loci in L5178Y/tk+/- mouse lymphoma cells: molecular and preliminary cytogenetic characterizations of AHA-induced tk-/- mutants.
Topics: Adenine; Animals; Blotting, Southern; Cell Survival; Chromosome Banding; Hypoxanthine Phosphoribosyl | 1991 |
Mutagenicity of 2-amino-N6-hydroxyadenine at the tk locus in L5178Y strains differing in repair capabilities and karyotype.
Topics: Adenine; Animals; Cell Survival; DNA Damage; DNA Repair; Free Radicals; Lymphoma; Mice; Mutagenicity | 1991 |
The mutagenicity of 2-amino-N6-hydroxyadenine to L5178Y tk +/- 3.7.2C mouse lymphoma cells: measurement of mutations to ouabain, 6-thioguanine and trifluorothymidine resistance, and the induction of micronuclei.
Topics: Adenine; Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Lymphoma; Mice; | 1991 |
Adenylate deaminase deficiency in a mutant murine T cell lymphoma cell line.
Topics: Adenine; AMP Deaminase; Animals; Blotting, Southern; Cell Division; Cell Line; Cell Survival; DNA, N | 1990 |
Expression of a novel high affinity purine base transport system in mutant mouse S49 cells does not require a functional nucleoside transporter.
Topics: Adenine; Animals; Biological Transport; Clone Cells; Dipyridamole; Dose-Response Relationship, Drug; | 1989 |
AMP deaminase and thymidine kinase deficiencies in a mutant mouse S49 cell clone.
Topics: Adenine; AMP Deaminase; Animals; Cell Division; Clone Cells; Dose-Response Relationship, Drug; Hybri | 1989 |
Distinct effects of adenine and guanine starvation on DNA synthesis associated with different pool sizes of nucleotide precursors.
Topics: Adenine; Animals; Cell Compartmentation; Cell Cycle; Cell Line; Deoxyadenosines; DNA Replication; DN | 1987 |
S49 mouse lymphoma cells are deficient in hypoxanthine transport.
Topics: Adenine; Animals; Biological Transport; Cell Line; Cricetinae; Cricetulus; Dipyridamole; Hypoxanthin | 1986 |
Chemotherapy of Herpesvirus saimiri induced lymphoma-leukemia in the owl monkey.
Topics: Adenine; Animals; Arabinose; Cyclophosphamide; Cytarabine; Disease Models, Animal; Haplorhini; Herpe | 1974 |
Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxy-adenosine and structurally related nucleoside analogs.
Topics: Adenine; Animals; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Diphosphates; Glucose; Glucosyltransfer | 1968 |
Inhibition of purine synthesis de novo in cultured L5178Y methylthioinosine.
Topics: Adenine; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cytosine Nucleotides; Guanosine Tri | 1973 |
Letter: The cytotoxic effects of a new antibiotic vermicule.
Topics: Adenine; Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Carbon Radioisotopes; Carcinom | 1974 |
Tissue-dependent differences in DNA methylation products of mice treated with methyl-labelled methylnitrosourea.
Topics: Adenine; Adenoma; Animals; Bone Marrow; Carbon Isotopes; DNA, Neoplasm; Guanine; Kidney; Liver; Lung | 1971 |
Nuclear uptake of exogenous DNA by mammalian cells in culture.
Topics: Adenine; Animals; Carbon Isotopes; Cell Nucleus; Chromosomes; Culture Techniques; DNA; Guanine; Lymp | 1968 |
Origin of urinary methylated purines.
Topics: Adenine; Animals; Carbon Isotopes; Guanine; Humans; Lymphoma; Male; Mammary Neoplasms, Experimental; | 1966 |
Studies on the biochemical mode of action of a cytotoxic methylhydrazine derivative, N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide.
Topics: Adenine; Amines; Animals; Antineoplastic Agents; Carbon Isotopes; DNA; Formates; Guanine; Hydrazines | 1966 |